cholesterol drug News
Most Popular cholesterol drug Story
Karo Bio walks away from Phase III cholesterol drug due to safety risks
Struggling biotech Karo Bio has nixed its lead program for the anti-cholesterol drug eprotirome and canceled plans to split the Swedish developer into two companies, one of which would have focused Read more...
Latest Headlines
- February 14, 2012
- November 11, 2011
- November 10, 2011
- October 31, 2011
- September 13, 2011
- November 18, 2010
- March 5, 2010
- November 6, 2008
- May 21, 2008
- April 30, 2008
- April 29, 2008
- March 31, 2008
- March 28, 2008
- January 16, 2008
- January 8, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
